Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Tuesday, 8 August 2017

MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group

MDxHealth (R)    

Published: 07:00 CEST 08-08-2017 /GlobeNewswire /Source: MDxHealth (R) / : MDXH /ISIN: BE0003844611

MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group

 

COMPANY ANNOUNCEMENT / REGULATED INFORMATION / INSIDE INFORMATION      

 

IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 8, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced it has signed a health care services agreement with Southern California Permanente Medical Group to assess the performance of the ConfirmMDx® for Prostate Cancer test.

 

Southern California Permanente Medical Group* is a physician-led organization that serves the 4.4 million members of Kaiser Permanente Southern California.

 

About ConfirmMDx for Prostate Cancer

ConfirmMDx for Prostate Cancer is the first epigenetic, and only tissue-based test in the 2016 NCCN Guidelines for early detection of prostate cancer which addresses false negative biopsy concerns. It is the only molecular diagnostic test that provides a very high negative predictive value (NPV) of 96% for clinically significant prostate cancers, and 90% NPV for all prostate cancers, as well as prostate mapping of the test results to help guide repeat biopsies. Each year, more than 1 million American men undergo an invasive prostate biopsy with a negative result, however approximately 30% of those men have prostate cancer. The current standard of care for prostate biopsy procedures samples less than 1% of the prostate, leaving men at risk for undetected cancer and leading to a high rate of repeat biopsies, even on cancer-free men. ConfirmMDx for Prostate Cancer helps urologists identify low-risk men who may forego an unnecessary repeat biopsy and high-risk men who may benefit from intervention. ConfirmMDx has qualified for Medicare reimbursement and covered by numerous private health insurance plans.

 

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth

 

For more information:

 

Shalon Roth, EVP Corporate Communications

MDxHealth

+44 (0)7393 906278

shalon.roth@mdxhealth.com

 

 

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

 

*This announcement is not intended to serve as an endorsement of MDxHealth or ConfirmMDx by Kaiser Permanente.

 



ConfirmMDx & Kaiser company announcement



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: MDxHealth (R), Rue d'Abhooz, 31, Herstal 4040, Belgique
If you would like to unsubscribe and stop receiving these e-mails click here.